Clinical trial
A study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 overexpressing oesophageal and gastric cancers
Is it possible to predict from the pretreatment tumour biopsies whether or not lapatinib will be effective at turning off HER2 signalling?
| Category | Value |
|---|---|
| Study start date | 2010-11-29 |